iifl-logo-icon 1

Gujarat Themis Biosyn Ltd Share Price

470.95
(-1.86%)
Jul 19, 2024|09:56:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open474.1
  • Day's High482
  • 52 Wk High530
  • Prev. Close479.9
  • Day's Low465
  • 52 Wk Low152.22
  • Turnover (lac)36.07
  • P/E58.96
  • Face Value1
  • Book Value27.72
  • EPS8.14
  • Mkt. Cap (Cr.)3,421.15
  • Div. Yield0.21
No Records Found

Gujarat Themis Biosyn Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

474.1

Prev. Close

479.9

Turnover(Lac.)

36.07

Day's High

482

Day's Low

465

52 Week's High

530

52 Week's Low

152.22

Book Value

27.72

Face Value

1

Mkt Cap (₹ Cr.)

3,421.15

P/E

58.96

EPS

8.14

Divi. Yield

0.21

Gujarat Themis Biosyn Ltd Corporate Action

3 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

14 May 2024

12:00 AM

Dividend

Dividend Amount: 0.25

arrow

13 May 2023

12:00 AM

Split

arrow

13 May 2023

12:00 AM

AGM

Announcement Date: 13 May, 2023

arrow

14 May 2024

12:00 AM

BookCloser

arrow

Gujarat Themis Biosyn Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Gujarat Themis Biosyn Ltd SHAREHOLDING SNAPSHOT

21 Jul, 2024|04:54 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 70.86%

Foreign: 0.00%

Indian: 70.86%

Non-Promoter- 2.62%

Institutions: 2.62%

Non-Institutions: 26.51%

Custodian: 0.00%

Share Price

Gujarat Themis Biosyn Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

7.26

7.26

7.26

7.26

Preference Capital

0

0

0

0

Reserves

194.11

141.88

96.06

62.68

Net Worth

201.37

149.14

103.32

69.94

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

90.56

85.12

38.79

35.69

yoy growth (%)

6.38

119.39

8.7

9.4

Raw materials

-15.37

-11.33

-2.15

-1.48

As % of sales

16.97

13.31

5.55

4.16

Employee costs

-7.11

-6.43

-4.45

-4.41

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

40.88

31.25

4.83

4.88

Depreciation

-1.73

-1.36

-1.14

-1.11

Tax paid

-10.7

-7.58

-0.97

-0.5

Working capital

34.58

16.25

0.88

3.46

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

6.38

119.39

8.7

9.4

Op profit growth

26.67

410.27

3.15

-0.1

EBIT growth

30.09

512.27

-0.7

5.32

Net profit growth

27.47

512.18

-11.65

-5.44

View Ratios

No Record found

Gujarat Themis Biosyn Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,593.65

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,582.3

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.05

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.3

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,665.1

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Gujarat Themis Biosyn Ltd

Management

Register Office

Registrar Office

Chairman & Non Executive Dir.

Dinesh S Patel

Non Executive Director

Sachin D Patel

Independent Non Exe. Director

VIJAY GOPI KISHAN AGARWAL

Independent Non Exe. Director

Kirandeep Madan

Independent Non Exe. Director

Vikram D Sanghvi

Independent Non Exe. Director

Siddharth Y Kusumgar

Company Sec. & Compli. Officer

RAHUL DWARAKA SONI

Independent Director

Hitesh Dharmasinh Gajaria

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL.During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the
Read More

Company FAQs

What is the Gujarat Themis Biosyn Ltd share price today?

Down Arrow

The Gujarat Themis Biosyn Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹470.95 today.

What is the Market Cap of Gujarat Themis Biosyn Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Themis Biosyn Ltd is ₹3421.15 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of Gujarat Themis Biosyn Ltd?

Down Arrow

The PE and PB ratios of Gujarat Themis Biosyn Ltd is 58.96 and 17.31 as of 19 Jul ‘24

What is the 52 Week High and Low of Gujarat Themis Biosyn Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Gujarat Themis Biosyn Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gujarat Themis Biosyn Ltd is ₹152.22 and ₹530 as of 19 Jul ‘24

What is the CAGR of Gujarat Themis Biosyn Ltd?

Down Arrow

Gujarat Themis Biosyn Ltd's CAGR for 5 Years at 127.70%, 3 Years at 73.31%, 1 Year at 203.62%, 6 Month at 55.74%, 3 Month at 25.28% and 1 Month at -0.14%.

What is the shareholding pattern of Gujarat Themis Biosyn Ltd?

Down Arrow

The shareholding pattern of Gujarat Themis Biosyn Ltd is as follows:
Promoters - 70.86 %
Institutions - 2.62 %
Public - 26.52 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.